Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark

COPENHAGEN, June 3 /PRNewswire/ — Santaris Pharma and Copenhagen
Institute of Technology, Aalborg University, Denmark, announced today that
Director of microRNA, Santaris Pharma, Sakari Kauppinen, has been appointed
Adjunct Professor in RNA Biology at Copenhagen Institute of Technology. The
appointment has immediate effect and will last five years. Sakari Kauppinen,
who will continue his in current role as Director of MicroRNA Research at
Santaris Pharma, will give his inaugural lecture in August this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

Sakari Kauppinen, Director of MicroRNA Research at Santaris Pharma said:

“I feel very honored to be appointed Adjunct Professor in RNA Biology at
the Copenhagen Institute of Technology, Aalborg University. Close
collaborations with academia are essential for Santaris Pharma’s expanding
microRNA therapeutics program, which aims at translating the basic knowledge
about microRNAs in disease into development of novel medicines with the
potential to improve human health. I am looking forward to interacting
closely with Aalborg University, whose experience in working with the biotech
industry is highly synergistic with our way of collaborating with academia.”

Soren Tulstrup, CEO of Santaris Pharma said:

“We are thrilled that Sakari Kauppinen has received this important
academic appointment. Sakari Kauppinen has helped bring Santaris Pharma to a
leadership position worldwide within the exciting new scientific field of
microRNA, and I am sure he will contribute significantly to the university in
his future additional capacity as Adjunct Professor.”

Lene Lange, Professor, Dr. Scient. Vice Dean for the Faculties of
Engineering, Science and Medicine, Aalborg University said:

“ Sakari Kauppinen is superbly qualified for the position as Adjunct
Professor at Copenhagen Institute of Technology, Aalborg University. The
decision was made based upon his groundbreaking work, his standing as an
international leader in the microRNA field, his service to the scientific
community, and his status as a valued and generous colleague. A close
relationship with the knowledge intensive private industry is very important
to Aalborg University, so the fact that Sakari Kauppinen can achieve this
stature while working as a scientist in Santaris Pharma makes him a truly
rare individual and even more valuable for Copenhagen Institute of Technology
and Aalborg University. The university is fortunate to have Sakari Kauppinen as a member of the Faculties of Engineering, Science and Medicine.”

http://www.santaris.com

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical
company developing new classes of RNA medicines targeting disease-related
mRNAs and miRNAs based on its proprietary LNA chemistry. The Company’s own
research and development activities focus on microRNAs, infectious diseases
and metabolic disorders. Santaris Pharma is leveraging its highly effective
and efficient Drug Discovery Engine to generate lead LNA drug candidates
against a broad array of disease targets selected by strategic partners. The
Company and its corporate partners currently have four compounds in clinical
development and a full pipeline in late preclinical development. Santaris
Pharma has since its inception raised nearly $100 million through private
financing and upfront payments.

    Contact

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com

SOURCE Santaris Pharma A/S